We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




First-Ever Blood Test Detects Parkinson’s Disease

By LabMedica International staff writers
Posted on 24 Jun 2022

Until now, the diagnosis of Parkinson's disease has been based primarily on typical movement disorders such as muscle stiffness, slower movements and shaking. More...

However, the disease starts up to 20 years before it becomes noticeable as a result of these symptoms. To date, there have been neither blood parameters nor imaging examinations to produce a definite diagnosis, let alone early recognition. Scientists around the world are looking for reliable clinically applicable biomarkers for this chronic progressive brain disease. Now, researchers have developed a method that reliably detects protein changes in blood that are typical of Parkinson's disease.

A research team at the Faculty of Medicine at Kiel University (‎Schleswig-Holstein‎, Germany) has developed a biochemical blood-based test for the diagnosis of Parkinson's disease. In a study, the test was able to distinguish the 30 Parkinson’s patients from the 50 control individuals with a very high degree of sensitivity. However, it is still no known whether early stages of the diseases can also be detected and whether the test will work for diseases that are similar to Parkinson’s.

The new method is based on three steps. The first step was to isolate the vesicles of nerve cells in the blood sample. Vesicles are small blisters that are pinched off cells and contain the protein of the original cell. The second step was to look specifically for the protein that causes the disease in these isolated nerve cell vesicles. This is a changed form of α-synuclein. This pathogenic form of α-synuclein can be detected through structure-specific antibodies. The third and most significant step of the detection method involves reproducing these misfolded α-synuclein forms of Parkinson’s patients from vesicles taken from patients’ blood.

“We developed a biochemical blood-based test for the diagnosis of Parkinson's disease. With our procedure, we were able to distinguish the 30 Parkinson’s patients from the 50 control individuals with a very high degree of sensitivity,” said Dr. Annika Kluge from the Faculty of Medicine at Kiel University. “The results are really sensational. They form the basis on which a blood test for diagnosing Parkinson's disease can be developed.”

Related Links:
Kiel University 


New
Gold Member
Collection and Transport System
PurSafe Plus®
Portable Electronic Pipette
Mini 96
New
Gold Member
Automated MALDI-TOF MS System
EXS 3000
Urine Chemistry Control
Dropper Urine Chemistry Control
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New evidence shows viscoelastic testing can improve assessment of blood clotting during postpartum hemorrhage (Photo courtesy of 123RF)

Viscoelastic Testing Could Improve Treatment of Maternal Hemorrhage

Postpartum hemorrhage, severe bleeding after childbirth, remains one of the leading causes of maternal mortality worldwide, yet many of these deaths are preventable. Standard care can be hindered by delays... Read more

Immunology

view channel
Image: The CloneSeq-SV approach can allow researchers to study how cells within high-grade serous ovarian cancer change over time (Photo courtesy of MSK)

Blood Test Tracks Treatment Resistance in High-Grade Serous Ovarian Cancer

High-grade serous ovarian cancer (HGSOC) is often diagnosed at an advanced stage because it spreads microscopically throughout the abdomen, and although initial surgery and chemotherapy can work, most... Read more

Industry

view channel
Image: Private equity firms Blackstone and TPG have joined forces to acquire Hologic in a major healthcare deal (Photo courtesy of Hologic)

Hologic to be Acquired by Blackstone and TPG

Hologic (Marlborough, MA, USA) has entered into a definitive agreement to be acquired by funds managed by Blackstone (New York, NY, USA) and TPG (San Francisco, CA, USA) in a transaction valued at up to... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.